Otorhinolaryngologic Manifestations in Leishmaniasis by Alves Mota, Luiz Alberto & Ferreira de Miranda, Roberta Correia Ribeiro
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Otorhinolaryngologic Manifestations in Leishmaniasis
Luiz Alberto Alves Mota and
Roberta Correia Ribeiro Ferreira de Miranda
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57303
1. Introduction
Leishmaniasis is considered by the World Health Organization (WHO) as one of the five
endemic infectious and parasitic diseases of greatest importance and as a world-wide public
health problem [1]. It is an infectious disease that evolves chronically and is caused by a
protozoon of the genus Leishmania, which may appear as a clinical form which is visceral,
cutaneous, mucocutaneous, mucousal and rarely diffuse [2]. The term Leishmaniasis refers to
the infection of vertebrate hosts Leishmania, which, like the other trypanosomatids of the order
Kinetoplastida, characteristically present an extranuclear DNA in its cytoplasm in a mito‐
chondrial organelle, the kinetoplast. This genus is characterized by having two ways of
evolving during its biological cycle in host organisms: amastigote, which is an obligatory
intracellular parasite in vertebrates, and promastigote, which develops in the digestive tube
of invertebrate vectors or in axenic culture media [3].
In 1903, the agent of the disease was first described and separately by Leishman and Donovan.
It is a protozoon identified in splenic tissue from two patients resident in India affected by a
fatal disease [4]. It is primarily a zoonotic infection of wild animals, and more rarely pets,
including marsupials, carnivores and even primates, with humans being accidental hosts.
All species of Leishmania are transmitted by the bite of female mosquitoes called phlebotominae
of the genera Lutzomyia and Phlebotomus, this transmission being made by inoculation of
promastigotes into the skin of the vertebrate host [5]. In larynegeal Leishmaniasis, contami‐
nation generally occurs starting with high lesions of the nasal cavities and oropharynx by
contiguity. It is rare for parasites to be found inside the lesions [6].
The incubation period ranges from 2 weeks to several months [13]. Mucosal involvement is
dependent on the combination of the virulence of the parasite and the immune cell response
of the host. Within the population of infected individuals, 1-10% experience mucosal involve‐
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ment [15]. Risk factors for the development of mucosal Leishmaniasis are: the presence of
lesions above the pelvis, large skin ulcers and inadequate treatment of cutaneous Leishma‐
niasis [3].
For the diagnosis of mucosal Leishmaniasis, the clinical history and typical cutaneous scars
have been considered as important clinical markers to corroborate the diagnosis of LM in
patients with non-specific nasal/ oral granulomatous lesions [20].
In the Americas, pre-Colombus pottery, made by the Indians of Peru, has been found, dating
from 400 to 900 AD. These show mutilations of lips and noses, characteristics of espundia,
today known as muco-cutaneous leishmaniosis. Subsequently, through studies in paleome‐
dicine, mummies with skin lesions and mucosas characteristic of Leishmaniasis were found
[9]. Historical findings suggest that American Cutaneous Leishmaniasis (ACL) already
affected the peoples of America before contact with Europeans and Africans. It is assumed that
it may have originated in the western Amazon region during archeological times by means of
human migrations and later ascended to the high jungle and then to the hot inter-Andean lands
across the frontiers of Bolivia and of Peru with Brazil [5].
In the Old World (Asia, Africa and Europe) written accounts of the disease date from the first
century AD. About two thousand years later, in 1903, the agent of the disease is described for
the first time and separately by LEISHMAN and DONOVAN. The disease was visceral
Leishmaniasis and its agent, the species now known as Leishmania donovani [4].
The first reference to American Tegumentary Leishmaniasis (ATL) in Brazil is in the document
of the Religious Political-Geographical Pastoral 1827, quoted in Tello’s book entitled "Anti‐
guidad de la Syfilis en el Peru", where he recounts the journey of Friar Don Hipólito Sanches
de Fayas y Quiros de Tabatinga (AM) to Peru, which crossed the regions of the Amazon basin
[9]. In 1911, GASPAR VIANNA gave the parasite found by Lindenberg the name Leishmania
brasiliensis, because he considered it morphologically different from Leishmania tropica. This
characterized, from then on, the etiological agent of the disease being referred to as "Bauru
ulcer", "angry angry" or "tapir-nose" [5].
In the 80s, the ATL was noted in 19 Federative Units (i.e. states), its geographical expansion
being verified when, in 2003, autochthony was confirmed in all Brazilian states. It is seen to be
widespread and, in some areas there is an intense concentration of cases, while in others, there
are isolated cases [7]. The disease has been described in almost all American countries, from
the extreme South of the United States to the North of Argentina, with the exception of Chile
and Uruguay [22].
2. Epidemiology
Leishmaniasis is the second most common parasitic disease in the world, with an estimat‐
ed 600,000 new cases per year [6]. It can also be considered an occupational disease, since
it has affected workers in mining areas, geologists, scientific expeditions, military person‐
nel in training [2]. It has been documented in several countries, with an estimated preva‐
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lence of 12 million worldwide [3]. More than 20 Leishmania species pathogenic to man have
been described.
Until the 1990s, the classification of these species was based primarily on clinical and geo‐
graphic criteria, taking into account on the one hand, the distinction between Old and New
World, and, on the other, the clinical forms of the disease. This type of classification which has
been progressively replaced by phylogenetic classification, is seen to be increasingly less tight
and more superficial [4].
Leishmaniasis species are widely distributed and have been documented in Africa, Europe,
Asia and America. In the Old World, L. tropica, L. major and L. aethiopica, which cause tegu‐
mentary Leishmaniasis, are identified as causal agents of the disease. In the Americas, several
species of Leishmania are capable of causing tegumentary Leishmaniasis, such as L. braziliensis
(LVB), L. amazonensis, L. guianensis, L. pananmensis and L. Mexicana.
The characterization of Leishmania species that was initially made, considering the behavior of
the parasite in the vector, today has biochemical and imminological and molecular biology
techniques, by isoenzyme analysis, reactivity with monoclonal antibodies and analysis of the
DNA of kinetoplast [3]. In the Americas, 11 dermotropic species of Leishmania causing human
disease are currently recognized and 8 species desrcibed as being only in animals [8].
It  is in Brazil  that the largest prevalence in the whole American continent is found, this
being estimated as 65,000 new cases per year [6]. The coexistence is observed of a double
epidemiological profile, expressed by the maintenance of cases coming from old foci or areas
near them, and by the appearance of epidemic outbreaks associated with factors arising
from  the  emergence  of  economic  activities,  such  as  mining,  expansion  of  agricultural
frontiers  and extractivism,  in  environmental  conditions  that  are  highly  favorable  to  the
transmission of the disease [8].
A great number of the houses in recent population settlements are built very close to the edge
of the forest and individuals are affected by the radius of action of these vectors that reach
houses and are also attracted by several factors such as lighting, the presence of sinantropic
animals such as Didelphis marsupialis, domestic animals and man himself [1]. Some species
of rodents, marsupials, edentates and wild canids have already been recorded as hosts and
possible natural reservoirs. The reservoir-parasite intersection is considered a complex system,
insofar as it is multifactorial, unpredictable and dynamic, and forms a biological unit which
can be in constant change as a result of the changes in the environment [8].
The disease occurs, more habitually, in the form of epidemic outbreaks. Thus, the degree of
exposure of the individuals affected is related directly to agricultural population settlements
which were planned or more often arise from occupation processes on the outskirts of a city,
most of which are disorganized [1].
Initially, the reservoirs of the mosquito transmitter were in the wild or in rural areas, but the
environmental transformations, provoked by the migratory process and by the increasing
urbanization have been modifying this profile. The adaptation of the vectors to the new
conditions enabled the disease to spread in the domiciliary and peri- domiciliary settings [5].
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In several regions of the country, such as in the South and Southeast, intense environmental
changes occurred due to anthropic action and agricultural and pastoral activities, which led
to the near disappearance of cutaneous Leishmaniasis in the late 40s. However, from the 70s
and 80s Leishmaniasis has reappeared in these regions, with a significant increase in the
number of new cases arising from endemic areas [1]. Transmission classically was due to the
bite of an insect, the so-called insect vector. This insect, also called a sandfly, belongs in the
Old World to the genus Phlebotomus, and in the New World, to the genus Lutzomyia [4].
The first cases of ATL in America date from 1885 and in Brazil, the first report was in 1909. In
the period 1985-1999, there were 388,155 auctothon cases in Brazil of ALT; from 1999 to 2003,
33,872 cases of ATL a year were registered [1]. In the period from 2000 to 2009, an average of
24,684 confirmed cases of Leishmaniasis was registered in Brazil the Information System for
Notifiable Diseases (SINAN) [14]. In 2003, the regions with the highest prevalence of LTA were
the North (14,200 cases) and the Northeast (8,005 cases) [5].
In Brazil, 23,399 confirmed cases of ATL were notified in 2009, of which 94.1% were new cases
and 4.6% relapses. With respect to clinical manifestations, 93.7% of patients had the cutaneous
clinical form and 6.2%, clinical mucosa. Of all patients, in 2009, only 73.5% [17, 23] were cured,
16 patients died due to ATL, and 122 died from other causes, noting that 21.2% there was no
information on the evolution of 21.2% of the cases [14].
It is estimated that every year there are new cases in Brazil and the growth of this number is
due in part to the emergence and growth of AIDS and deforestation areas [2]. It mostly affects
young and adult males [16]. The greater number of cases of American Tegumentary Leish‐
maniasis among men and adults suggests extra-domiciliary transmission in the economically
active population, while this occurrence among women, children and people with non-
agricultural occupations suggests intra- and or peridomiciliary transmission.
The transmission of ATL in the Amazon presents a clear seasonal variation, it being more
intense in the rainy season, when the temperature, solar radiation and evaporation are lower
and humidity higher, thus favoring an increase in the density of the phlebotominae, including
the species involved in the cycle of the disease [1]. In endemic areas, there may be significant
percentages of children with the disease [16].
3. Etiological agents and vectors
In the Americas, 11 dermotropic species of Leishmania which cause the disease in humans
are  currently  recognized  and  8  species  have  been  described  as  affecting  only  animals.
However, in Brazil,  7 species, there being 6 of the subgenus Viannia  and 1 of the subge‐
nus Leishmania, have been identified. The three main species are: Leishmania ( Leishmania)
amazonensis  -  distributed throughout  the  primary  and secondary  forests  of  the  Amazon
(Amazonas,  Pará,  Rondônia,  Tocantins  and  the  southwest  of  Maranhão  southwest),
particularly in igapó and forest areas of the "swamp-forest" type. Its presence extends to the
regions  of  the  Northeast  (Bahia),  Southeast  (Minas  Gerais  and São Paulo)  and Midwest
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(Goiás); Leishmania (Viannia) guyanensi - apparently limited to the north of the Amazon Basin
(Amapá, Roraima, Amazonas and Pará) and extending to the Guianas. It is found mainly
in terra firme  forests in areas that do not flood during the rainy season; Leishmania (Vian‐
nia) braziliensis – is widely distributed, from the South of Pará to the Northeast, also reaching
the center-south of the country and some areas of the Eastern Amazon East. In the Amazon,
the infection is usually found in dry land areas.
As the subgenus Viannia, there are other species of Leishmania that have been recently descri‐
bed: L. (V) lainsoni, L. (V) naiffi with a few human cases in Pará; L. (V) shawi, with human cases
found in Pará and Maranhão. More recently, the species L. (V.) lainsoni, L. (V.) naiffi, L. (V.)
lindenberg and L. (V.) shawi were identified in states of the North and Northeast regions [8]. In
areas of transmission of L. braziliensis concomitantly or after resolution of the cutaneous
disease, about 3% of patients with cutaneous Leishmaniasis will develop the mucosal form of
the disease [3].
Mucosal Leishmaniasis (ML) is a form of tegumentary Leishmaniasis associated with L.
braziliensis, L. panamensis and less frequently with L. amazonensis [11]. The vectors of ATL are
insects known as phlebotominae, belonging to the order Diptera, Psychodidae family, sub-family
Phlebotominae, genus Lutzomyia, popularly known, depending on the geographical location, as
straw-mosquito straw, tatuquira, birigui, among others [8]. Generally not exceeding 0.5 cm in
length, with long and spindly legs and a dense body follicles. A characteristic of theirs is a
hopping flight and keeping their wings erect, unlike other dipteral [9]. The vectors are Lutzomya
anduzei, Lutzomyia whitmani and Lutzomyia umbratilis, which is the main vector, which usually
lands during the day on tree trunks and attacks people in large numbers, when disturbed [16].
It is usually brownish ("straw-mosquito"), only the females being adapted with the respective
mouth part to prick the skin of vertebrates and suck blood.
The genus Lutzomyia is responsible for the transmission of Leishmaniasis in the Americas, and
there are 350 species catalogued, which are distributed from the South of Canada to the North
of Argentina. Of these, at least 200 occur in the Amazon basin. Very little is known of their
breeding grounds, with immature forms being found in debris of rock crevices, caves, roots
of the soil and of dead and damp leaves, and also in the forks of trees in animal burrows - ie
in moist but not wet soil, and in debris rich in decaying organic matter [9].
4. Clinical state
Tegumentary Leishmaniasis is more common than the visceral disease and is characterized in
its classical form by the presence of a well-bounded ulcer with raised edges. [17] ATL is an
initial infection of the skin (its site of preferential location) from which it can undergo propa‐
gation or a secondary process which goes on to manifest itself in the mucosae of the upper
airways [5]. The incubation period of the disease in humans is, on average, 2 months, it being
possible for there to be shorter (two-week) periods and longer periods (of up to 2 years) [16].
The disease breaks out, in general, during the first five years that follow the appearance of the
skin lesion, but may do so even a few decades after the primary cutaneous lesion, the scar from
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which can still be seen. However, in some patients the disease appears primarily in the mucosa
membrane, without leaving traces on the skin. [2]. The most common manifestation is
leishmaniotic ulcer: a single skin ulcer or only in small numbers, with raised edges, framed
and the absence of local pain. Other morphological features can also be identified, such as:
infiltrated plaque, tubercule, nodule and verrucous vegetating lesion. When the mucosa is
injured, it can present an infiltrated erythema, granular or ulcerated aspect. In order of
frequency, mucosal lesions are manifested mainly in the nose, hard palate, pharynx and larynx,
which they can present themselves with an erythematous-infiltrated, granular, ulcerated or
polypoid aspect with a roughly rounded surface [5].
Basically, it is possible to do the staging of the lesions that have occurred in the ATL by taking
into consideration the time of onset, extent and spread of the lesion, and grouping them into:
1). Primary infections: which characterizes the primary accident (initial injury) or leishmaniotic
cancer, found at the site of the bite, and after the incubation period (two weeks to one year),
erythematous papules appear that progress to forming ulcers with serosanguinous crusts. 2)
The onset of secondary Leishmaniasis ranges from one to three months after the primary
infection, involving the skin, lymph nodes, lymphatic organs and mucosa and by contiguity,
the mucous membranes of the nose, lips, eyelids and genitals are affected when the primary
or secondary lesions settle near these regions. 3) Tertiary Leishmaniasis requires a longer
period to appear, generally, five to ten years after the initial lesion and is characterized by the
presence mainly of naso-oro-pharyngeal, laryngeal and ocular lesions, and it is in this period
tertiary that the primary infection has already disappeared and the secondary one, in general,
is still present [5]. The clinical presentation exhibits polymorphism and the spectrum of
severity of the signs and symptoms is also variable, although there is a certain correspondence
between the different clinical presentations and the different species of the parasite [7].
Mucosal Leishmaniasis appears under the following clinical forms: 1) Late –this is the most
common form. Classically, it is associated with multiple or long-lasting skin lesions, sponta‐
neous cures or insufficient CL treatments; 2) Of undetermined origin - when the ML is clinically
isolated, it not being possible to detect any other evidence of prior CL; 3) Concomitant - when
the mucosal lesion occurs at a distance, but at the same time as the active skin lesion (not
contiguous to the natural orifices); 4) Contiguous – this occurs by direct propagation of the
skin lesion, located next to natural orifices, to the mucosa of the aerodigestive tracts. The skin
lesion may be in activity or healed at the time of diagnosis; 5) Primary – this occurs, possibly,
by the bite of the vector in the mucosa or semimucosa of lips and genitals [7.8].
It is believed that untreated mucosal lesions are progressive, there being few reports of
spontaneous cicatrizations of these lesions which, even if treated, may leave permanent
sequelae [22]. There are several hypotheses that attempt to explain the predilection of the nasal
mucosa: direct contact of the hand with the skin lesions and scratching one´s nose afterwards,
the epithelium of the anterior part of the nasal cavities offer conditions to the location of
Leishmanias and the lower temperature in the anterior area of the nasal septum, due to the
presence of a current of inspiratory air. The transition zone between the squamous epithelia
and the pseudostratified vibrating, in the anterior part of the nasal septum and the lower
turbinate head, is the "locus minoris resistentia" to the Leishmaniasis process. However, the most
Leishmaniasis - Trends in Epidemiology, Diagnosis and Treatment50
consistent hypothesis says that Leishmania requires lower temperatures for its growth. Thus,
since the anterior area of the nasal septum is cooler due to the inspiratory airflow, there would
be a predilection for proliferation of the parasites [13]. The association of low temperature with
Leishmaniasis may, in part, be explained by the documentation in vitro that macrophages
grown at 29°C are less able to destroy Leishmania than macrophages cultured at 33°C [3].
It occurs more often in males and at age bands usually higher than CL, which is probably due
to its character of secondary complication [8]. The involvement of the nasal and/or mucosa is
usually more severe and thus may cause sequelae and death [20].
The initial lesion is characterized by a whitish nodulation without ulceration which is usually
observed in the cartaliginous septum (Kiesselbach’s area), the floor and side wall, specifically
on the head of the inferior turbinate. This impairment classified as stage I of the disease,
represents a very early stage of inflammation and does not resemble, from the clinical
standpoint, any other nasal disease. Subsequently, a fine granular lesion appears, character‐
ized by superficial ulceration, documented at the anterior septum, inferior turbinates and floor
of the nasal cavity (Stage II) [17]. At first, there is hyperemia and edema of the mucosa of the
anterior septum, with the establishment of nodulations [3].
In Stage III, or the stage of deep ulceration, tissue reaction is more intense, with aberrant
granulation tissue and infiltration of the mucosa, thus widening the nasal septum. There is
sometimes edematous infiltration of the nasal pyramid itself. In this phase, hematic crusts can
be observed on the septum, the inferior turbinates and the floor of the nasal cavities. These
lesions are characterized by excessive fragility, as they bleed very easily when the mucosa is
touched.
Clinically, the patient may complain of soreness at the level of the nasal pyramid, sanguinolent
rhinorrhea and emission of hematic crusts. Nasal obstruction is a frequent symptom in this
phase of the disease. From the external point of view, due to the inflammatory process that
involves the cartilages and subcutaneous cell tissue and the very skin of the base of the nasal
pyramid, the nose takes on the aspect known as tapir-nose.
Stage IV of the disease is  characterized by the cartilaginous involvement of the anterior
septum with necrosis and, sometimes, impairment of the columella. It is at this stage that
perforation of the cartilaginous septum is established, also with marked infiltration of the
posterior septum. In more advanced forms (Stage V), total destruction of the columella may
occur and may drop, thus transforming the nasal cavity into a similar cloaca and some‐
times there is perforation of the dorsum of the nasal pyramid [17]. For some researchers,
the specific destruction of the nasal cartilage could also indicate an autoimmune reaction
that would explain why some patients undergo severe tissue destruction and others only
present mucosal involvement years later [21].  In some cases there may be total  destruc‐
tion of the anterior septum, only the entire columella remaining, with the nose being sealed.
Extensive  crusts  of  a  hemorrhagic  aspect  or  even  resulting  from the  drying  of  mucous
secretion  caused  by  enlargement  of  the  internal  nasal  structure  can  be  observed  as  a
consequence of the tissue injury, represented by the destruction of the cartilaginous septum
and inferior turbinates. On this occasion, there is elimination of sanguinolent discharge and
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the presence of  crusts  is  accentuated [17].  The patient's  death usually occurs because of
aspiration or respiratory failure [5].
The earliest signs and symptoms of mucosal Leishmaniasis are nasal obstruction, epistaxis and
the establishment of granulomas in the anterior nasal septum. As the disease evolves, patients
begin to present a leishmaniotic facies known as "tapir nose" due to edematous infiltration of
the lining and supporting structures of the nose [3]. Lesions reach the cartilaginous nasal
septum and may extend to the lateral wall and floor, the region of the palate, uvula, and less
frequently, involvement of the pharynx, larynx, vocal cords and upper lip occur with varying
degrees of infiltration, granulation and ulceration [17]. The infiltration of the soft palate reaches
the proportions of a real tumor. The whole palate is changed: the uvula is reduced to a shapeless
mass, with an irregular, vegetating surface. In the palatal vault, lobed prominences are formed,
separating themselves by sinuous furrows and ulcerated erosions.
More rarely it can involve the gum and dental interstices, where voluminous and prominent
granulations develop, and reach the upper lip. The tongue is usually spared [5]. The manifes‐
tations of the mucosal diseases include involvement of pillars and uvula with an increase in
volume, hyperemia, roughness and superficial ulcers [12]. The pharynx is the second site of
involvement when mucosal lesions caused by L. braziliensis set in. As in the nose, the lesion
initially observed at the level of the mucosa of the pharynx takes on a lumpy aspect; however,
here, there is a much more intense edematous infiltration, especially of the uvula and secon‐
darily of the tonsillar pillars, extending also to the mucosa of the posterior pharyngeal wall.
The appearance can be observed at this stage of granulation tissue that is a little redundant
intermingled with the lumpy aspect of the mucosa. The next stage is characterized by the
appearance of abundant granulation tissue, which causes important tissue destruction, also
involving the lymphoid tissue of Waldeyer's lymphatic ring at the level of tonsils. Areas with
a tenuous fibrin layer mix in with the granulation tissue of a vegetating aspect.
Because of the intense tissue aggression, in the specific post-treatment healing process, the
presence of abundant fibrous tissue, with the formation of true whitish cords can be docu‐
mented. These completely deform the configuration of the anatomical structures of the velum
of the palate and the posterior wall of the pharynx, leading to full stenosis in the communica‐
tion of the oropharynx with the nasopharynx [3]. In the mouth, the hard palate is often
involved, with dissemination of the process to the soft palate, uvula and pharynx. The
proliferating infiltrative process can cause fusion of the uvula, pillars, lateral cords and
posterior wall, causing obliteration of the nasopharynx. Deformity and narrowing of the lumen
of the oropharynx may occur due to fibrosis of the tonsils [5].
Laryngeal mucosa is the 3rd site of election when mucosal Leishmaniasis sets in. As in the
pharynx, the mucosal lesions present the same characteristics of finely granular tissue. There
may be in situations of greater inflammation, the presence of granulation tissue with a
vegetating aspect, covered at times with a tenuous fibrin layer, involving the mucosa that
covers the cartilage of the epiglottis, extending to the mucosa of the structures of the laryngeal
vestibule and vocal folds. At this stage, dysphonia characterized by a muffled voice is always
present, which draws attention to the impairment of the organ [3]. Pharyngolaryngeal
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involvement can be intense, to the point of causing dysphagia, dyspnea, dysphonia, odyno‐
phagia, and coughing [15]. The hypopharynx, larynx, epiglottis, arytenoid cartilages and the
posterior commissure of the vocal cords are covered by a lesion with a vegetating aspect, which
sometimes come to join up. These granulations often regress and eventually disappear, making
the surface affected by a smooth and slightly whitish coloration.
There is generalized laryngeal inflammation particularly in the piriform sinuses. The vocal
folds appear to be moving well, but phonation is weak and the muscular control of tension
can be harmed by granulomatous formation and subsequent fibrosis. Even after successful
treatment, the voice rarely returns to normal and the lumen of the larynx may be reduced [5].
Painful dysphagia in degrees of greater or lesser intensity prevents the normal feeding of the
individual, with consequent impairment of general condition and, in very advanced cases,
becoming cachexia. In post-treatment healing, the deformities that these cartilages present are
very evident, such as fibrous tissue which is also whitish, thereby completely modifying the
anatomy of the organ, except for a residual permanent dysphonia [3].
Complications include pneumonia due to aspiration, bacterial infections, secondary myiasis,
cachexia due to difficulties in swallowing, laryngeal edema and asphyxiation, which may be
lead on to the patient's death mainly due to respiratory failure and sepsis [5]. The presentation
of the clinical form with lesions exclusive of mucosa of the larynx and trachea is relatively
uncommon [2]. The ear is not usually affected in mucosal Leishmaniasis. However, the
involvement of the mucosa of the nasopharynx leads to impairment of the pharyngeal orifice
of the Eustachian tube, situated on its sidewall. A process of otitis media with effusion
(secretory otitis media chronic) can be established in these cases.
The sensation of blocked ear, tinnitus and hearing loss are complaints in these cases [3].
Morbidity of the skin and ear cartilage occurs because it is a place of lower temperature, apt
for the growth of Leishmania, besides being an area exposed to the inoculation of the vectors.
The external ear commonly presents an increase in volume, ulcers with raised edges, some‐
times covered with crusts, and may appear as an infiltrated plate, tubercule, vegetating warty
nodule and lesion, on course in the end to mutilating the ear [5].
Mucosal Leishmaniasis can compromise the labial mucosa and gingival margin. This is a rarer
manifestation of the disease [3]. The lesion in some individuals heals early, sometimes without
seeking medical attention. Others remain for months with the lesion in activity and the healing
process is slow. This phenomenon can be explained by the rapid or late establishment of a
specific immune response which is effective in eliminating the parasite.
The cure of Leishmaniasis is not sterile. It has been possible to isolate viable parasites of ALT
scars in individuals who have been cured for several years, a fact confirmed in experimental
studies using an animal model. This phenomenon could thus explain the appearance of late
relapses as well as the onset of the disease in immunocompromised patients, such as AIDS
(Acquired Immunodeficiency Syndrome) [7].




It is very hard to detect Leishmaniasis in the initial stage [15]. The long interval between the
onset of symptoms and etiological diagnosis of the mucosal form of ATL may reflect the
limitation of the training of most physicians in the proper approach to mucosal Leishmaniasis
[2]. A laryngoscopy exam usually demonstrates an extensive inflammatory component, with
erythema and edemas evident. The granulomatous aspect associated with the presence of
ulcers is common, and may present purulent exudate. In the advanced disease, tissue destruc‐
tion can be striking. As a protocol of etiological investigation on suspicion of granulomatous
bodies that are difficult to access such as the larynx, laboratory tests and imaging should be
requested, and should a diagnostic uncertainty be maintained, a biopsy of the lesions is
recommended for histological study. If the appearance of the lesion suggests malignant
neoplasm, research using noninvasive and invasive tests should occur simultaneously so as
not to delay diagnosis [15].
The ENT examination associated with the Montenegro test remains the most important
element for diagnosis, although it is usually of a presumptive character [20]. The encounter of
Leishmania is the gold standard for the diagnosis of ATL [21]. The diagnosis can be confirmed
by various tests: 1) Direct investigation of the parasite, which can be done by scraping the
ulcerated surface or by compression of the slide on the wounded area of the lesion. The material
is stained with Giemsa or Wright [2]. The direct parasitological examination is the procedure
of first choice because it is faster, less expensive and easy to perform [16]. It gives good results
in initial lesions, without associated bacterial infection [2], 2) Montenegro intradermoreaction:
This translates the response of cell delayed hypersensitivity [16]. It consists of intradermal
injection of 0.1 ml of antigen prepared from Leishmania promastigotes, with a reading after 48
hours. The test is considered positive that produces an induration of 5 mm or more. However,
the positivity of the test indicates that the person has already been sensitized but is not
necessarily a carrier of the disease [2]; 3) Histopathological examination of the tegumentary
lesion [2]. The Biopsy can be performed with a "punch" of 4 mm in diameter, or a wedge, with
the use of a scalpel. In ulcerated lesions, the whole edge of the whole lesion should be preferred,
This, in general, shows a tumified and hyperemic aspect [16]; 4) Serology (indirect immuno‐
fluorescence or ELISA); they have good sensitivity but can give a reaction crossed with Chagas
disease and visceral Leishmaniasis, this being the cause of false-positive results, thus reducing
its specificity [2].
The most commonly used techniques for antibodies are: indirect immunofluorescence (IIF),
counterimmunoelectrophoresis (CIE ), ELISA and Western blot. The Western blot technique
has a superior sensitivity to the other serologic techniques [70.6%), a sensibility of 70.3% and
a precision of 72.7%. In the immunocompetents, the specificity and sensitivity are 100% [4]; 5)
Immunohistochemical techniques (immunostaining with anti Leishmania antibodies); they
permit evidence of the parasite in histological sections; 6) Method of culture: culture takes
place in Novy-MacNeal-Nicolle medium from the biopsy or aspirate [4]. They are not practical
for diagnosis, especially of Leishmania brasiliensis, since it does not grow easily in culture media;
in addition, bacterial or fungal contamination often complicate this procedure [2]. Research
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can be done into Leishmania in other affected organs such as the spleen, liver and lymph node,
and whenever there is a suspected diagnosis, into the pleural fluid, bronchoalveolar lavage,
intestinal biopsy, skin, etc. Hepatic and spleen biopsies are used as a last resort due to the
increased risk of potentially serious complications such as hemorrhaging [4].
Cases are confirmed according to the following criteria: 1) Residence, arrival in or moving
away from the area with confirmation of transmission and presence of the parasite in direct
and/or indirect parasitological exams; 2) Residence, arrival in or moving away from the area
with confirmation of transmission and intradermoreaction of Montenegro (MRI) positive, 3)
Residence, arrival in or moving away from the area with confirmation of transmission with
other methods of positive diagnosis [19].
6. Differential diagnosis
The finding of symptoms and head and neck moles in patients with Leishmaniasis, paracoc‐
cidioidomycosis and leprosy underscore the need that they all undergo an ENT evaluation. In
addition to these diseases, it would be an appropriate conduct to perform complete ENT
examination in all patients with some form of granulomatous disease [11]. The differential
diagnosis of laryngeal ATL is made with granulomatous lesions such as tuberculosis and
paracoccidioidomycosis which have a predilection for the posterior portion of the larynx [2].
The diagnosis of paracoccidioidomycosis is characterized by erosion or exulceration in the oral
mucosa, with a granulous base and the presence of stippled hemorrhage (Aguiar Puo’s
moriform stomatitis), regional lymph node and lung involvement [8]. Syphilitic laryngitis,
which fortunately nowadays is rare and appears in the tertiary stage of syphilis may present
diffuse infiltrate, which subsequently undergoes ulceration [2]. Tertiary syphilis can be
confirmed by histopathological exam, and shows vascular lesions and plasma cell wealth, and
VDRL may be positive [8].
Neoplastic lesions of the larynx are more localized and almost always there is a report of
smoking and alcoholism in the medical history [2]. Epidermoid and basal cell carcinomas
usually present themselves as hardened to palpation, and are confirmed by histopathological
examination [8]. Histoplasmosis in its chronic disseminated form involves mucosa in 90%, and
the upper airways are affected; the larynx is very adversely affected with infiltration and
edema of the laryngeal vestibule, pink nodules on an infiltrated base and granulomatous
ulcerations of a granulomatous depth partially covered by yellowish-white secretions that may
lead to obstructive dyspnea, requiring a tracheostomy. Generally, in this form of presentation
of histoplasmosis there will be alterations in the chest X-ray associated with pulmonary
symptoms, which differentiates it from Leishmaniasis. Coccidioidomycosis of the larynx is
very rare in our environment. Tracheobronchial amyloidosis with involvement of the larynx
is very rare; however, it may present itself with pseudotumoral, bleeding, warty lesions, with
a visual appearance similar to the case presented, which can lead to obstruction of the airways
[2]. The differential diagnosis is made with rhinophyma, rhinosporidiosis, entomophthoro‐
mycosis, traumatic septal perforation or because of drug use, allergic rhinitis, sinusitis,
sarcoidosis, Wegner's granulomatosis and other rarer diseases.
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As for lymphomas, histopathological and immunohistochemical exams will help to conclude
the diagnosis. In the case of rhinophyma, there is usually a history of rosacea (acne-like lesions
and telangiectasias, of long evolution). In the differential diagnosis with rhinosporidiosis what
are important are: the origin (Piauí, Maranhão), the history of possible exposure to the fungus
in stagnant water and dams, the presence of polyps in the nasal and ocular mucous membranes,
and upper respiratory tracts. Histopathological examination shows the microorganism
(sporangia of 6 to 300μm). Lesions of entomophthoromycosis present a hardened or woody
consistency to palpation and histopathological and mycological exams demonstrate the
presence of hyphae and isolation of the fungus in cultur medium. In the differential diagnosis
with leprosy, skin sensibility tests, testing of skin bacilli in the lymph of the pinna or lesions
and histopathological examination will help confirm the diagnosis. The clinical history is
essential when seeking information on personal or family atopy (allergic rhinitis, bronchitis,
migraine), on traumatic perforation and use of drugs. Wegner's granulomatosis and sarcoi‐
dosis are rarer diseases, and sometimes difficult to confirm. Diagnosis may be aided by
observation of the involvement of other organs such as the lungs and kidneys, it being stressed
that the histopathology will contribute to the diagnosis [8].
7. Co-infection Leishmania and HIV
ATL can modify the progression of the disease due to HIV and immunosuppression caused
by this virus facilitating progression of ATL [8]. Acquired immunodeficiency syndrome is
caused by a retrovirus of the Lentiviridae family, HIV-1 and HIV-2. Those infected with the
human  immunodeficiency  virus  (HIV)  progress  to  severe  dysfunction  of  the  immune
system, as the CD4 + T lymphocytes, one of the major target cells of the virus, are being
destroyed [19]. On destroying the immune system, the so-called "opportunistic infections"
are  manifested  as  this  unfolds  in  which  infections  are  included,  namely  infections  by
protozoa [4]. The assessment of the set of clinical manifestations of ATL in patients with
HIV  indicates  that  there  is  no  definition  of  a  clinical  profile  that  may  unarguably  be
associated with  co-infection [8].  The  exponential  increase  in  the  number  of  cases  of  co-
infection of Leishmania/ HIV, especially in the late 1990s, has undergone modifications [4].
Unusual  findings  can  be  observed  in  co-infected  patients,  suchas,  for  example,  finding
Leishmania spp in intact skin, and overlying a Kaposi's sarcoma lesion, or Herpes simplex and
Herpes zoster  lesions. There may also be involvement of the gastrointestinal tract and the
respiratory tract for the coinfection of ATL/AIDS [8].  The population of drug users who
inject  endovenously  is  the  main  group  at  risk  of  the  co-infection  of  Leishmania/HIV  in
Southeast Europe, and form 72% of co-infected patients [4].
8. Prevention
Several thorough trials have been carried out on the production of anti- Leishmania vaccines:
1) "Leishmanization" has been used empirically since the distant past by people living in
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endemic areas. This consists of scarification covered with virulent promastigotes of virulent
to avoid the appearance of disfiguring lesions in exposed areas. 2) The association of BCG with
dead Leishmania promastigotes. 3) Vaccines produced by molecular technology from DNA,
probably the future of prophylaxis in infectious diseases in immunosuppressed patients [4].
9. Treatment
ENT activity is of primary importance [5]. The drug of first choice is the pentavalent antimonial
one. With a view to standardizing the therapeutic regimen, WHO recommends that the dose
of this antimonial be calculated in mg /SbV/ Kg day./ (SbV meaning a pentavalent antimonial).
There  are  two  types  of  pentavalent  antimonial  that  can  be  used,  N-methylglucamine
antimonate and sodium stibogluconate [10,16].  In all  forms of mucosal involvement,  the
recommended  dose  is  20mg  Sb+5/kg/day,  for  thirty  consecutive  days,  preferably  in  a
hospital environment. If healing is not complete within three months (twelve weeks) after
treatment ends, the scheme should be repeated only once. Should there be no response, use
one of the second choice drugs [16].
If there is no satisfactory response to the treatment with pentavalent antimony, the second
choice drugs are amphotericin B and pentamidine isethionate. The injections must be made
parenterally, intramuscularly (IM) or intravenously (IV), with rest after application. The IM
may have the drawback of local pain. It is suggested, therefore, locations be alternated, the
gluteal region being preferred.
In cases of malnourished patients with low muscle mass, and those with thrombocytopenia,
the intravenous route should be given preference. This is the best route because it allows the
application of large volumes without the inconvenience of local pain. The application should
be slow (a minimum of 5 minutes), with a fine needle (gauge 25x7 or 25x8) and without needing
to be diluted. To make it possible for rest after administration, it is generally advisable to apply
the medication at the end of the day. It is worth noting that there is no difference between the
IV and IM routes, with respect to the efficacy and safety of the drug [8].
The use of topical products such as paromomycin and imiquimod, associated or not with
parenteral medication, have also presented preliminary satisfactory results, with cure rates
ranging between 74% and 85% for the former drug, and 90% for the latter [9]. The imidazo‐
quinoline, approved for the treatment of genital warts, [17] stimulates the Th1 response by
increasing the production of TNF- α, IFN-γ and IL-12. In vitro, presents anti Leishmanial
activity because it also stimulates the production of nitric oxide by macrophages, thus
decreasing the number of parasites. Paromomycin is an antibiotic that inhibits the mitochon‐
drial activity of Leishmania. rhGM-CSF is a glycoprotein that induces the growth of colonies of
granulocytes and/or macrophages, by stimulating their phagocytic and metabolic functions.
For this reason, it plays an important role in the immune response against intracellular
pathogens. It has been used experimentally in the treatment of some inflammatory diseases
as it has an inhibitory effect on TNF- α [18].
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Local treatment of small lesions may not be necessary. Larger lesions may be treated with
surgical excision, curettage or cryotherapy [13]. Secondary infection may occur in 54.2% of
patients and the germ most frequently found is Staphylococcus aureus [21], which is why local
care should be prescribed such as local cleansing with soap and water and if possible com‐
presses with KMnO (potassium permanganate in a dilution of 1/5000ml) [8, 16].
The cure criterion is defined by the regression of all signs and confirmed by ENT examination,
up to 6 months after completion of the treatment regimen. In the absence of the specialist, the
clinician must be trained to perform, at least, anterior rhinoscopy and oroscopy. Where there
is no clinician, the patient should be referred to the service that evaluates healing. The patient
should return monthly for a consultation for 3 consecutive months after the end of the
treatment regimen so that the clinical cure can be evaluated.
Once cured, the patient should be monitored every 2 months, until 12 months after completing
treatment [8]. The control of ATL should be tackled in a comprehensive way, in five respects:
epidemiological surveillance, measures of performance in the transmission chain, educational
measures, administrative measures and vaccine [9]. To reduce the lethality of these diseases,
what is above all necessary is early diagnosis and the timely treatment of cases [14].
The current challenges for ATL are: a) to increase investments in seeking drugs with better
efficacy, safety, low cost, ease of administration and sustainability; b) to continue to be vigilant
about the adverse effects of medication; c) to expand the health network for early diagnosis
and adequate treatment of cases; d) to investigate and evaluate deaths; e) to implement
surveillance actions in territorial units; f) to expand the activities of epidemiological surveil‐
lance [19].
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